This cluster is routine, all sales follow option vesting/exercise events and are immaterial by dollar size. No bearish read-through. Monitor next earnings (likely catalyst) or any material clinical update given the biotech sector context. The 95% analyst bullish consensus remains unchanged.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 12 $112.41entry
- T+1 · 3mo ago −2.50%α −3.20% · $109.60
- T+5 · 3mo ago +1.15%α +1.59% · $113.70
- T+20 · 2mo ago −8.12%α −6.22% · $103.28
- T+60 · 12d ago −26.15%α −21.04% · $83.01
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Multiple Dianthus Therapeutics insiders, including CEO Marino and GC Veness, executed open-market sales totaling $3.15M over a 7-day window, with $1.12M (CEO) and $1.78M (GC) concentrated on a single day. The sales are likely liquidity-driven following vesting and option exercises (non-cash derivatives), but the CEO's involvement and total value relative to the $6.5B market cap (0.048%) suggests routine portfolio diversification rather than a bearish signal.
Key Financial Metrics
Key Facts
- 4 insiders sold a total of ~$3.15M in open-market transactions from Aug 7-10, 2026.
- CEO Marino sold 10.4K shares at $107.49 for $1.12M on Aug 7.
- GC Veness sold 16.2K shares at $110.38 for $1.78M on Aug 10.
- Total insider sales represent 0.048% of $6.5B market cap, well below any material threshold.
- All sales coincided with option exercises (non-cash derivative exercise events on the same dates).
Financial Impact
Total insider sales of $3.15M represent less than 0.05% of market cap, economically insignificant.
Risk Factors
- No open-market buys from any insider to counterbalance selling.
- If stock declines >10%, the lack of insider buying could amplify selling pressure.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-DNTH-1786775156334 |
Track record
23 reports on DNTH
7 of 8 bullish or bearish reports moved the stock their way by T+1. Best: +41.40% at T+60 after the Jun 11, 2026 report. 8 of 8 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $89.76 Now $89.55 −0.23% settles Nov 17
- Nov 9, 20267d ago 144 Neutral 3/10 Entry $88.81 to $89.30 Now $89.55 +0.83% ▲ +0.55% −0.77% vs SPY
- Nov 4, 202612d ago 8-K Neutral 4/10 No price data
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $83.01 to $86.03 Now $89.55 +7.88% ▲ +3.64% +3.33% vs SPY
- Oct 30, 202617d ago Institutional Cluster Neutral 3/10 Entry $82.38 to $82.25 Now $89.55 +8.70% ▼ −0.16% +0.32% vs SPY
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $82.38 to $82.25 Now $89.55 +8.70% ▼ −0.16% +0.32% vs SPY
- Oct 12, 20265w ago Institutional Cluster Mixed 3/10 Entry $81.57 to $77.58 Now $89.55 +9.78% ▼ −4.89% −4.88% vs SPY
- Aug 11, 202613w ago Insider Cluster Neutral 4/10 Viewing Entry $112.41 to $109.60 Now $89.55 −20.34% ▼ −2.50% −3.20% vs SPY
- Aug 11, 202613w ago Insider Cluster Neutral 3/10 Entry $112.41 to $109.60 Now $89.55 −20.34% ▼ −2.50% −3.20% vs SPY
- Aug 11, 202613w ago Insider Cluster Neutral 3/10 Entry $112.41 to $109.60 Now $89.55 −20.34% ▼ −2.50% −3.20% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers